News
Novartis acquires Kate Therapeutics
Novartis has acquired Kate Therapeutics, a San Diego-based, preclinical stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined...
European Commission approves Pfizer’s HYMPAVZI for adults and adolescents with severe hemophilia A or...
The European Commission (EC) has granted marketing authorization for Pfizer's HYMPAVZI (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of...
Glox Therapeutics awarded £1m PACE grant to accelerate development of precision antibiotics against antimicrobial-resistant...
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, has secured £1 million in grant funding from...
